United Therapeutics (NASDAQ:UTHR) Director Sells $701,800.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) Director Christopher Patusky sold 1,210 shares of United Therapeutics stock in a transaction on Monday, November 9th. The shares were sold at an average price of $580.00, for a total transaction of $701,800.00. Following the completion of the transaction, the director owned 2,140 shares in the company, valued at approximately $1,241,200. This represents a 36.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $593.31 on Friday. The company has a 50-day simple moving average of $540.58 and a 200-day simple moving average of $535.80. United Therapeutics Corporation has a one year low of $455.63 and a one year high of $614.23. The stock has a market capitalization of $25.27 billion, a price-to-earnings ratio of 22.39, a PEG ratio of 3.99 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share for the quarter, missing the consensus estimate of $6.01 by ($0.30). United Therapeutics had a return on equity of 19.18% and a net margin of 38.61%. The business had revenue of $832.50 million for the quarter, compared to analyst estimates of $781.14 million. During the same quarter last year, the company posted $7.16 EPS. United Therapeutics’s quarterly revenue was up 4.1% on a year-over-year basis. As a group, research analysts forecast that United Therapeutics Corporation will post 24.90 EPS for the current fiscal year.

United Therapeutics declared that its Board of Directors has initiated a stock buyback plan on Thursday, October 22nd that authorizes the company to buy back $2 billion in outstanding shares. This repurchase authorization authorizes the biotechnology company to repurchase up to 8.3% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of analysts have weighed in on UTHR shares. HC Wainwright initiated coverage on United Therapeutics in a research report on Monday. They set a “buy” rating and a $660.00 price objective for the company. Raymond James Financial set a $720.00 target price on United Therapeutics in a report on Wednesday, November 4th. The Goldman Sachs Group reissued a “sell” rating and issued a $368.00 target price on shares of United Therapeutics in a report on Thursday, October 15th. JPMorgan Chase & Co. cut their price target on United Therapeutics from $710.00 to $695.00 and set an “overweight” rating for the company in a research note on Wednesday, October 28th. Finally, Weiss Ratings downgraded United Therapeutics from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday. Twelve research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $676.40.

Institutional Trading of United Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Meeder Advisory Services Inc. lifted its position in United Therapeutics by 3.0% in the third quarter. Meeder Advisory Services Inc. now owns 657 shares of the biotechnology company’s stock valued at $356,000 after purchasing an additional 19 shares during the period. Benjamin Edwards Inc. boosted its holdings in United Therapeutics by 5.1% in the 3rd quarter. Benjamin Edwards Inc. now owns 497 shares of the biotechnology company’s stock valued at $269,000 after purchasing an additional 24 shares in the last quarter. First Trust Advisors LP increased its position in United Therapeutics by 40.4% during the 3rd quarter. First Trust Advisors LP now owns 349,666 shares of the biotechnology company’s stock worth $189,480,000 after purchasing an additional 100,610 shares during the period. Allianz SE acquired a new position in United Therapeutics during the 3rd quarter worth approximately $182,000. Finally, Advisors Asset Management Inc. acquired a new position in United Therapeutics during the 3rd quarter worth approximately $23,850,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Trending Headlines about United Therapeutics

Here are a few of the latest headlines about UTHR:

• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $660 price target. Its forecasts point to rising EPS, from $27.46 in FY2026 to $53.67 in FY2030, suggesting expectations for substantial longer-term earnings growth. HC Wainwright coverage article
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares for about $5.64 million, reducing her direct stake by 2.84%; she still owns about 324,443 shares. Director Christopher Patusky also sold 1,210 shares for $701,800, a 36.12% reduction in his position. Insider selling can create a near-term sentiment overhang, although it does not by itself indicate a change in the company’s outlook. CEO sale report Director sale report

About United Therapeutics

United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.